Foamix Fortifies Its Patent Position in Mexico
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, announced today that the Company has obtained another granted patent in Mexico. - June 05, 2012
Foamix Obtains US Patent "Waterless Hydrophilic Foam" for Dermatological and Gynecological Drugs, Such as Antibiotics, Antifungals and Corticosteroids
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office. - April 27, 2012
Foamix’s Minocycline Foam – 100% Effective in Impetigo Phase II Clinical Trial with No Side Effects. 80% Improved Significantly After 3 Days of Treatment.
Targets a $1 billion a year market. Foamix, a clinical stage specialty pharmaceutical company, announced today the successful completion of the Phase II clinical trial of Minocycline foam in Impetigo patients. Minocycline Foam has shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA). - March 20, 2012
Foamix Granted Comprehensive US Patent for PerFoam® – Ideal Foam Treatment for Head Lice and Scabies
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office. - March 15, 2012
Foamix Obtains US Patent for Iodine Foam – Innovative Treatment for Heat Burns and Warfare Materials, as Well as Fungal and Bacterial Infection
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office. - March 13, 2012
New Foamix US Patent: "Foamable Compositions, Kits and Methods for Hyperhidrosis" - First in Class Foam for Excessive Sweating
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office. - March 13, 2012
Foamix Obtains India Patent for Its Emollient Foam Platform – The Ideal Vehicle for Dermatological Drugs
Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a patent from Indian Patent Office # IN 249626, entitled “Foam Carrier Containing Amphiphilic Copolymeric Gelling Agent.” - February 10, 2012
Survey Reveals: 77% of Dermatologists Will Prescribe Topical Minocycline. Foamix’s First-in-Class Minocycline Foam - Now in Phase II
Most Dermatologists are concerned with Oral Minocycline side effects and will prefer prescribing their patients Topical Minocycline for Rosacea, Acne, Skin Infections and Chronic Wounds. - August 02, 2011
Arkin and Foamix to Develop an Innovative Acne Foam
Arkin Holdings and Foamix today announced that they have established a collaboration to develop and commercialize an innovative topical foam to treat patients with acne vulgaris and related disorders. - May 27, 2011
Foamix Announces Phase II Clinical Trial of Topical Minocycline Foam for Rosacea
The first-in-class topical Minocycline product, protected by 4 patent applications, is directed for the treatment of Rosacea, Acne, Skin Infections and Chronic Wounds - January 20, 2011
Foamix Receives US Patent for Oleaginous Foam
Oleaginous Foams – Ideal Vehicles for Lipophilic and Water-Sensitive Drugs, such as Vitamin D, Retinoids and Lipophilic Antibiotics. - November 06, 2010
Foamix and BioMAS to Develop Novel Therapy for Genital Warts
The New Drug Will Target One of the Most Common Sexually Transmitted Disease, Afflicting More Than 20 Million Americans. - November 03, 2010
New U.S. Patent Grant to Foamix for Its Hygroscopic and Waterless Breakable Foam Technology
The patent describes unique pharmaceutical foams and their use to deliver a wide range of active agents to treat skin and body cavity conditions. - May 21, 2010
Foamix Receives a New U.S. Patent for Its Emollient and Aqueous Foam Technology
The Patent Covers Foams with Urea, Lactic Acid, Salicylic Acid and Penetration Enhancers - May 01, 2010